Company: ABUS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001447028-25-000115
Chunk: 27

Company: Arbutus Biopharma Corp
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 27
---
 $— $10,784 $10,784 Level 1Level 2Level 3TotalAs of December 31, 2024(in thousands)AssetsCash and cash equivalents$36,330 $— $— $36,330 Investments in marketable securities, current— 86,293 — 86,293 Total$36,330 $86,293 $— $122,623 LiabilitiesContingent consideration$— $— $10,225 $10,225 Total$— $— $10,225 $10,225 The following table presents the changes in fair value of the Company’s contingent consideration:  Liability at beginning of the periodChange in fair value of liabilityLiability at end of the period(in thousands)Six Months Ended June 30, 2025$10,225 $559 $10,784 Six Months Ended June 30, 2024$7,600 $391 $7,991 

See Note 4 for additional information regarding the fair value of the Company’s investments in marketable securities. 

 9

4.    Investments in marketable securities 

Investments in marketable securities consisted of the following:Amortized CostGross Unrealized Gain(1)Gross Unrealized Loss(1)Fair ValueAs of June 30, 2025(in thousands)Cash equivalentsMoney market funds$30,400 $— $— $30,400 Total$30,400 $— $— $30,400 Investments in marketable short-term securitiesUS corporate bonds$11,300 $9 $— $11,309 US treasury bills47,128 — (10)47,118 US government bonds2,250 — (1)2,249 Total$60,678 $9 $(11)$60,676  (1) Gross unrealized gain (loss) is pre-tax and is reported in accumulated other comprehensive income (loss). Amortized CostGross Unrealized Gain(1)Gross Unrealized Loss(1)Fair ValueAs of December 31, 2024(in thousands)Cash equivalentsMoney market funds$29,533 $— $— $29,533 Total$29,533 $— $—